Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026PRNewsWire · 3 days ago
Nuvation Bio Inc. (NYSE:NUVB) Stock Rated “Moderate Buy” by Wall Street AnalystsDefense World · Sep 30, 2026
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung CancerPRNewsWire · Sep 17, 2026
Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha · Sep 15, 2026
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung CancerPRNewsWire · Sep 15, 2026
Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha · Sep 9, 2026Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.14 | -$0.15 | Miss |
| May 4, 2026 | -$0.03 | $0.01 | Beat |
| Mar 2, 2026 | -$0.11 | -$0.11 | Beat |
| Nov 3, 2025 | -$0.17 | -$0.16 | Beat |
| Aug 7, 2025 | -$0.17 | -$0.17 | Beat |
| May 7, 2025 | -$0.16 | -$0.16 | Beat |